Biggest News Aggregation in the World
📰 Nasdaq Cccc News

Page 2 - Nasdaq Cccc News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Cccc. Real-time updates on events, politics, business and more.

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has been given a consensus recommendation of “Hold” by the seven research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have issued a buy recommendation on the […]
Tower Research Capital Therapeutics Company Profile Citigroup Inc Sohn Co Therapeutics Inc Get Free Report

Examining the Volatility of C4 Therapeutics Inc.'s (CCCC) Stock

The stock of C4 Therapeutics Inc. (CCCC) has seen a -11.48% decrease in the past week, with a -21.02% drop in the past month, and a -13.57% decrease in the past quarter. The volatility ratio for the week is 4.37%, and the volatility levels for the past 30 days are at 4.53% for CCCC. The simple movin
Koppikar Utpal View Research Zacks Investment Research Therapeutics Inc Credit Suisse Grand View Research

C4 Therapeutics (NASDAQ:CCCC) Price Target Cut to $20.00

C4 Therapeutics (NASDAQ:CCCC – Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a research note published on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Evercore ISI lowered their price objective on shares of C4 Therapeutics to $10.00 in a report on Tuesday, May […]
United States Dimensional Fund Advisors Arrowmark Colorado Holdings Capital Management Therapeutics Inc Free Report

C4 Therapeutics (NASDAQ:CCCC) Given New $20.00 Price Target at UBS Group

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) had its price objective decreased by UBS Group from $22.00 to $20.00 in a report issued on Friday, FlyOnTheWall reports. UBS Group’s price target would indicate a potential upside of 468.18% from the stock’s current price. Several other equities research analysts have also issued reports on the company. […]
United States Arrowmark Colorado Holdings Therapeutics Company Profile Capital Management Dimensional Fund Advisors Therapeutics Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.86 Average PT from Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) have received an average recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. […]
United States Lazard Asset Management Principal Financial Group Inc Ensign Peak Advisors Inc Therapeutics Company Profile Morgan Stanley

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $10.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target lowered by Evercore ISI to $10.00 in a report released on Tuesday morning, The Fly reports. Several other research firms also recently weighed in on CCCC. Credit Suisse Group raised shares of C4 Therapeutics from an underperform rating to a neutral rating and decreased their […]
United States Jpmorgan Chase Co Sohn Co Principal Financial Group Inc Ensign Peak Advisors Inc Therapeutics Inc
Source: wkrb13.com

Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $9.83

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has been assigned an average rating of “Hold” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The […]
United States Jpmorgan Chase Co Susquehanna International Group Ameriprise Financial Inc Geode Capital Management Therapeutics Inc

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average […]
United States Ensign Peak Advisors Inc Lazard Asset Management Therapeutics Company Profile Morgan Stanley Credit Suisse Group
Source: wkrb13.com

HC Wainwright Cuts C4 Therapeutics (NASDAQ:CCCC) Price Target to $25.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target cut by HC Wainwright from $35.00 to $25.00 in a research report report published on Monday, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings at […]
United States Hong Kong Cresset Asset Management Hong Kong Ltd York Mellon Corp Credit Suisse Group

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science